through proprietary devices that enable direct antibiotic treatment of infected joints

About Us

The Challenge

Periprosthetic Joint Infection (PJI) is devastating to patient health, frustrating to surgeons, and costly to the healthcare system.  

PJI presents as Acute, Chronic or Hematogenous.  This is a growing problem.  Without infection control improvement, the estimated WW treatment cost in 2020 is $1.6B.

Our Mission

ForCast Orthopedics is improving outcomes through proprietary total joint arthroplasty devices that enable direct antibiotic treatment of joints for remediation of infection whenever it occurs.  We believe this can lead to lower patient morbidity and treatment cost.     

Executive Summary

Click on a file to download.

Contact Us

Forcast Orthopedics

Regulatory Status

 ForCast Orthopedics and the ACE Knee Spacer has not yet been reviewed or cleared for use in the United States by the Food and Drug Administration.   It is currently not available for sale.   This is a solicitation for investment and corporate relationships